XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Other Financial Statement Information - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Concentration Risk [Line Items]      
Debt securities, available-for-sale, realized gain (loss) $ 0 $ 0  
Transaction price allocated to remaining performance obligations 33,500,000    
Deferred revenue 20,949,000   $ 20,658,000
Contract liability 33,500,000   $ 24,100,000
Gain on settlement 9,200,000 0  
Revenue 154,883,000 141,006,000  
Recognized foreign currency transaction income (loss) (1,500,000) 1,000,000.0  
Vizgen, Inc.      
Concentration Risk [Line Items]      
Amount of litigation settlement and intellectual property license granted 26,000,000    
Gain on settlement $ 9,200,000    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01      
Concentration Risk [Line Items]      
Expected period of revenue recognition 12 months    
Computer equipment and software      
Concentration Risk [Line Items]      
Impairment of long lived assets $ 100,000 2,100,000  
Cost of revenue      
Concentration Risk [Line Items]      
Impairment of long lived assets   300,000  
Research and development      
Concentration Risk [Line Items]      
Impairment of long lived assets   700,000  
Selling, general and administrative      
Concentration Risk [Line Items]      
Impairment of long lived assets   1,100,000  
Products and Services, Excluding Grant Revenue      
Concentration Risk [Line Items]      
Deferred revenue 20,900,000    
License and royalty revenue      
Concentration Risk [Line Items]      
Revenue 17,060,000 $ 1,000  
License and royalty revenue | Vizgen, Inc.      
Concentration Risk [Line Items]      
Revenue $ 16,800,000